PhotonPharma
Private Company
Funding information not available
Overview
PhotonPharma is a private, pre-revenue biotech focused on a novel cell therapy platform that uses light (riboflavin and UV) to create replication-incompetent tumor cells from a patient's own tumor sample. This 'Innocell' product serves as a personalized vaccine, presenting the full spectrum of a patient's tumor neoantigens to stimulate a potent and broad anti-cancer immune response. The company has received FDA clearance to initiate a Phase 1 safety and immunogenicity study in recurrent epithelial ovarian cancer, marking a key transition from preclinical validation to clinical development. Leadership includes seasoned veterans from academia, medical device, and pharmaceutical regulatory affairs, providing a blend of scientific innovation and industry execution expertise.
Technology Platform
Innocell™ platform uses riboflavin and ultraviolet (UV) light treatment to create replication-incompetent, autologous tumor cells that serve as a personalized vaccine, presenting a patient's full tumor neoantigen profile to stimulate an anti-cancer immune response.
Opportunities
Risk Factors
Competitive Landscape
Competes in the personalized cancer vaccine space against companies using mRNA, peptide, and dendritic cell platforms. Also faces indirect competition from broader immuno-oncology agents (checkpoint inhibitors, CAR-T for solid tumors). Key differentiator is the presentation of the full tumor antigen repertoire via a simple photochemical process.